Results 221 to 230 of about 125,585 (295)
Dentifrices for preventing erosive tooth wear: An in vitro comparative study
Abstract Erosive tooth wear is a progressive condition that compromises enamel structure and requires preventive strategies. This in vitro study aimed to compare the protective effects of fluoride‐based dentifrices containing various bioactive agents on sound enamel subjected to simulated erosive–abrasive challenges.
Juliellen Luiz da Cunha +6 more
wiley +1 more source
Immunodeficiency Diseases and Tumor Immunobiology [PDF]
Abramoff, Peter A., Duquesnoy, Rene J.
core +1 more source
Abstract Background Retrobulbar anaesthesia (RBA) is relevant for ocular surgery in standing sedated horses. Objectives Gathering insights on experiences with RBA techniques. Study Design Cross‐sectional survey. Methods An online survey collected information on the respondents' professional background, indications, injection methods, use of ultrasound ...
Simona Lieberth +4 more
wiley +1 more source
Delayed Hypersensitivity Reaction to OnabotulinumtoxinA. [PDF]
LeWitt PA.
europepmc +1 more source
Repeated paclitaxel exposure causes long‐lasting nociceptor hyperexcitability and axonal retraction in adult sensory neurons. Using a long‐term primary nociceptor culture, we show that hyperexcitability is mediated by sequential upregulation of NaV1.8, TRPV1, TRPA1, and TRPM8 channels.
Angela Lamberti +3 more
wiley +1 more source
The role of PARs in platelet function is fairly known; however, the underlying mechanisms are not fully understood. We report that thrombin myristoylates PAR4 in mouse platelets and PAR1 and PAR4 in human platelets, facilitating their membrane transport and interaction, leading to PAR3/4 heterodimers in mice and PAR1/4 heterodimers in humans.
Suresh Govatati +4 more
wiley +1 more source
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
ABSTRACT Introduction Valoctocogene roxaparvovec is an adeno‐associated virus vector serotype 5 (AAV5)‐mediated gene therapy for severe haemophilia A (HA). Aim Report the final safety and efficacy results of the phase 1/2 trial of valoctocogene roxaparvovec. Methods An open‐label phase 1/2 trial (NCT02576795) enrolled adult males with severe HA (factor
Priyanka Raheja +9 more
wiley +1 more source

